AMD

The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

Rachelle Lin, OD, MS, FAAO, and Quan Đông Nguyễn, MD, MSc, presented available treatment options and what is coming down the pipeline for retinal conditions.

From Stargardt to macular telangiectasia type 2, Kensington Hatcher, OD, FAAO, FORS; and Srinivas Kondapalli, MD, detail other conditions that share similarities to AMD.

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

In light of trial results, the company is preparing for financial outcomes dependent on its Development Funding Agreement, warranting a reexamination of Opthea's future.

The grant will allow the research team to determine the novel mechanisms that convert immature eye lens precursors cells into functional transparent cells.

The company also reported a positive outcome of an analysis of masked data from its ongoing MAGNIFY Phase 2 trial for zervimesine in adults with GA.

The study examined changes in genes and proteins of the retinas of 9 strains of mice.

A total of 150 placements are for aspiring optometrists to shadow SpaMedica’s clinical teams and in-house optometrists as they treat patients.

The goal of the agreement is to advance Eleva’s current programs into mid- and late-stage clinical development.

Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.

Results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively.

The company's lead product candidate Duravyu (vorolanib intravitreal insert), f/k/a EYP-1901, is anticipating topline data from several clinical trials in 2026.

The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

Nocturnal hypoxia could be a new additional modifiable risk factor for nAMD.

The potential gene therapy candidate is being evaluated for geographic atrophy.

Let’s look back on some of the top stories on Modern Retina from 2024 as we gear up for an incredible 2025.

A look at the biggest news and advancements in ophthalmology in 2024.

Reviewing new AMD treatments and research can help optometrists prepare for what's to come in 2025.

Mice with reduced levels of ERCC1-XPF in the study presented abnormal optokinetic and electroretinogram responses consistent with photoreceptor dysfunction and visual impairment.

Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections.

Building on previous RPE patch research, the research team aims to advance the therapy to early-stage human trials.

The study evaluates Duravyu’s efficacy, durability, and re-dosing every 6 months in both treatment-naïve and previously treated patients.

The company begins phase 1 trials of oral GAL-101, targeting amyloid beta aggregation for potential treatment of dry AMD, glaucoma, and neurodegenerative eye diseases.

The trial is expected to close randomization in early December 2024.

Key findings from the data include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option.